To qualify for this distinction, venture-backed privately held companies were valued in a funding round at $1 billion or more.
To understand 2019 through a different lens, let’s switch gears from the 2019 new unicorn cohort to funding to all unicorn companies.
It is worth noting that 2018 included two of the largest rounds ever to unicorn companies with $14 billion invested in Ant Financial, and $12.8 billion in Juul.
2019 new unicorn companies collectively added $216 billion to unicorn valuations, and $50.5 billion in equity funding in total over time.
All of these companies had an increased valuation at their IPO over their last private funding round in 2019, ranging from 25 percent for Health Catalyst to 189 percent for 10X Genomics.
With $50 billion invested in this new unicorn cohort, it is interesting to look at the investors fueling the growth of these companies.
The most active investors in companies that became unicorns in 2019 by portfolio count include the following:
The most active investors by deal count, which showcases investors who are in multiple rounds for companies who joined the unicorn ranks in 2019 include the following: New Enterprise Associates in 30 rounds, Insight Partners (26), Kleiner Perkins and GV (25), Accel and Spark Capital (24).
While there is no shortage in funding for these high-value companies, there remains a discrepancy between the number of male and female founders that reach the coveted unicorn status.